<DOC>
	<DOCNO>NCT02205450</DOCNO>
	<brief_summary>The PWS genetic disease intellectual disability associate multiple manifestation body system . It characterize hypothalamic-pituitary abnormality severe hypotonia early year life , condition feed difficulty . Hyperphagia appear later , cause severe obesity pre - school age . Other endocrine abnormality associate produce short stature , GH deficiency hypogonadotropic hypogonadism . These patient also vary cognitive dysfunction associate well learn problem , compound development psychological-psychiatric behavioral problem language . The aetiology GH decrease secretion SPW controversial , know IGF -1 level reduce child adult PWS . The rational use GH derive knowledge comorbidities observe PWS , seem relate GH deficiency : hypotonia , alter body composition , decreased growth , even obesity . â€¢ The GH accept since 2000 treatment PWS . Following fatal episode country , decide start treatment 2 year age arbitrary manner , U.S. France . Subsequent study find GH per se risk factor mortality . The currently publish data support benefit GH treatment start 4 6 month life , even expert advocate start 3 month , due lack consensus age onset treatment , despite benefit home early age onset obesity often start around 2 year life . HYPOTHESIS The use GH safe effective patient PWS child 2 year old .</brief_summary>
	<brief_title>Experience With Growth Hormone ( GH ) Children Under 2 Years With Prader-Willi Syndrome ( PWS ) Pediatric Endocrine Department Hospital Sabadell</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Prader-Willi Syndrome</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Children 2 year</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>2 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Prader-Willi Syndrome</keyword>
	<keyword>Growth Hormone</keyword>
	<keyword>Children</keyword>
</DOC>